DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.

Phase 2

Active, not recruiting

Conditions: Beta-thalassemia

Interventions: Drug: Placebo
Drug: Luspatercept

First Posted Date: 2022-10-05

Last Posted Date: 2025-02-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 90

Registration Number: NCT05567458

Locations: 🇨🇳
Local Institution - 0002, Maoming, Guangdong, China
🇨🇳
Local Institution - 0005, Shenzhen, Guangdong, China
🇨🇳
Local Institution - 0007, Liuzhou, Guangxi, China

and more 7 locations

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986369

First Posted Date: 2022-10-05

Last Posted Date: 2023-02-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT05567510

Locations: 🇺🇸
Labcorp Clinical Research Unit - Madison, Madison, Wisconsin, United States

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Phase 2

Terminated

Conditions: Alopecia Areata

Interventions: Drug: Deucravacitinib
Other: Placebo

First Posted Date: 2022-09-27

Last Posted Date: 2025-02-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 94

Registration Number: NCT05556265

Locations: 🇺🇸
Local Institution - 0013, Houston, Texas, United States
🇵🇱
Local Institution - 0025, Warsaw, Poland
🇺🇸
Local Institution - 0012, Austin, Texas, United States

and more 25 locations

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Phase 2

Terminated

Conditions: Cardiomyopathy, Hypertrophic

Interventions: Drug: MYK-224

First Posted Date: 2022-09-27

Last Posted Date: 2025-04-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT05556343

Locations: 🇺🇸
Local Institution - 0014, Los Angeles, California, United States
🇺🇸
Local Institution - 0016, San Francisco, California, United States
🇺🇸
Local Institution - 0026, La Jolla, California, United States

and more 22 locations

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Phase 3

Recruiting

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Mezigdomide
Drug: Dexamethasone

First Posted Date: 2022-09-23

Last Posted Date: 2025-04-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 525

Registration Number: NCT05552976

Locations: 🇨🇳
Local Institution - 0058, Kunming, Yunnan, China
🇩🇪
Universitaetsklinikum Heidelberg, Heidelberg, Germany
🇺🇸
USA Mitchell Cancer Institute, Mobile, Alabama, United States

and more 212 locations

A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque Psoriasis

Completed

Conditions: Psoriasis

First Posted Date: 2022-09-21

Last Posted Date: 2023-12-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3506

Registration Number: NCT05547490

Locations: 🇨🇳
Local Institution - 0001, Nanjing, Jiangsu, China
🇨🇳
Local Institution - 0002, Beijing, Beijing, China

A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986322
Other: Placebo for BMS-986322

First Posted Date: 2022-09-19

Last Posted Date: 2023-06-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT05546151

Locations: 🇺🇸
Anaheim Clinical Trials Llc, Anaheim, California, United States

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Advanced Solid Tumors
Non-small Cell Lung Cancer

Interventions: Biological: BMS-986442
Biological: Nivolumab
Drug: Docetaxel
Drug: Carboplatin
Drug: Pemexetred
Drug: Paclitaxel

First Posted Date: 2022-09-16

Last Posted Date: 2025-03-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT05543629

Locations: 🇺🇸
Local Institution - 0019, Cincinnati, Ohio, United States
🇮🇹
Local Institution - 0077, Siena, Toscana, Italy
🇺🇸
Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States

and more 29 locations

A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants

Completed

Conditions: Healthy Participants

First Posted Date: 2022-09-14

Last Posted Date: 2022-12-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 10

Registration Number: NCT05539976

Locations: 🇺🇸
Local Institution - 0001, Woburn, Massachusetts, United States

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

Early Phase 1

Terminated

Conditions: Healthy Participants

Interventions: Drug: BMS-986421
Other: Placebo

First Posted Date: 2022-08-26

Last Posted Date: 2023-09-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 46

Registration Number: NCT05517837

Locations: 🇺🇸
Local Institution - 0001, Cypress, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy